IGF1R and cancer: A monoclonal antibody against IGF-1R, AMG-479, and its kinase inhibitor, MK0406, effectively inhibit the proliferation of ovarian tumor cells and enhance tumor sensitivity to chemotherapeutic drugs such as cisplatin and taxane, which indicates that IGF-2 is an effective target for cancer therapy [55].